ℹ️
🇨🇿
Hledání
Hledat publikace relevantní k dotazu "Aldo-keto reductase 1C3"
Aldo-keto reductase 1C3
Publikace
Předměty
Osoby
Publikace
Studium
publication
Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
2014 |
Farmaceutická fakulta v Hradci Králové
publication
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism
2021 |
Farmaceutická fakulta v Hradci Králové
publication
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
2019 |
Farmaceutická fakulta v Hradci Králové
publication
AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types
2017 |
Farmaceutická fakulta v Hradci Králové
publication
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters
2022 |
Farmaceutická fakulta v Hradci Králové
publication
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Farmaceutická fakulta v Hradci Králové
publication
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
2020 |
Farmaceutická fakulta v Hradci Králové
publication
Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters
2019 |
Farmaceutická fakulta v Hradci Králové
publication
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
2020 |
Farmaceutická fakulta v Hradci Králové